859-90 (Nifedipine 60760 859 90)
Nifedipine Tablet, Extended Release
Product Images NDC 60760-859
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 60760-859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
01 (Image 01)
02 (Image 02)
This table displays the adverse effects reported by individuals taking Nifedipine extended-release tablets compared to a placebo. The adverse effects include headache, fatigue, dizziness, constipation, and nausea. The percentage of individuals experiencing these side effects is provided for both Nifedipine and placebo groups.*
03 (Image 03)
This table presents the comparison of adverse effects experienced by individuals taking nifedipine capsules versus those who took a placebo. The total number of participants in each group is provided within parentheses. Some of the reported adverse effects and their respective percentages for both groups include dizziness, lightheadedness, giddiness (27% nifedipine vs. 15% placebo), flushing, heat sensation (25% nifedipine vs. 8% placebo), headache (23% nifedipine vs. 20% placebo), weakness (12% nifedipine vs. 10% placebo), and more. The comparison indicates the incidence rates of each adverse effect to help evaluate the differences between the two groups.*
04 (Image 04)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
